Heart Failure Management in the Modern Era: A Comprehensive Review on Medical and Device-based Interventions

Heart failure remains a significant global health challenge, necessitating continuous advancements in management strategies to improve patient outcomes. This review aimed to elucidate the current scenario of heart failure and its management in the modern era, focusing on integrating medical therapy and implantable device interventions. According to guidelines, medical treatment remains the primary method of treating heart failure. Such medications include ACE inhibitors, neprilysin-angiotensin receptor inhibitors, beta-blockers, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, and blockers of sodium-glucose co-transporter- 2. These pharmacologic agents have demonstrated efficacy in decreasing mortality and morbidity in patients. The advent of implantable devices has revolutionized treatment, providing substantial benefits in specific patient populations. Cardiac resynchronization therapy has emerged as a pivotal intervention for patients with reduced ejection fraction and dyssynchronous ventricular contraction, effectively enhancing cardiac function and quality of life. Furthermore, left bundle branch area pacing improvements provide fascinating alternatives to traditional cardiac resynchronization therapy. The essential significance of device-based therapies is further highlighted by the function of implanted cardioverter-defibrillators in preventing unexpected cardiac deaths in high-risk patients. Furthermore, integrating remote monitoring technologies and novel device innovations continues to enhance the precision and efficacy of heart failure management. This review comprehensively examines current guidelines and evidence supporting the use of these therapies, addressing their synergistic potential and the practical considerations for their implementation, while synthesizing recent advancements in pharmacologic and device-based interventions.